Patient-reported Adherence to Triple Therapy (Aspirin/Antiplatelet; Beta Blocker; and Statin) at 6 Months 6 months [clinicaltrials_resource:b08b6421536d3fbb23e5d9a983ff4cbf]
Percent of patients in each group adherent to triple therapy (aspirin/antiplatelet; beta blocker; and statin) 6 months after discharge as assessed by medication history obtained during a follow-up phone call by a blinded pharmacist
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]
Patient-reported Adherence to Triple Therapy (Aspirin/Antiplatelet; Beta Blocker; and Statin) at 6 Months 6 months [clinicaltrials_resource:b08b6421536d3fbb23e5d9a983ff4cbf]
Percent of patients in each group adherent to triple therapy (aspirin/antiplatelet; beta blocker; and statin) 6 months after discharge as assessed by medication history obtained during a follow-up phone call by a blinded pharmacist
Bio2RDF identifier
b08b6421536d3fbb23e5d9a983ff4cbf
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:b08b6421536d3fbb23e5d9a983ff4cbf
measure [clinicaltrials_vocabulary:measure]
Patient-reported Adherence to ...... ocker; and Statin) at 6 Months
time frame [clinicaltrials_vocabulary:time-frame]
description
Percent of patients in each gr ...... e call by a blinded pharmacist
identifier
clinicaltrials_resource:b08b6421536d3fbb23e5d9a983ff4cbf
title
Patient-reported Adherence to ...... d Statin) at 6 Months 6 months
@en
type
label
Patient-reported Adherence to ...... b6421536d3fbb23e5d9a983ff4cbf]
@en